Drug Trial Radar · NCT00490139
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,381
Actual
Start
May 16, 2007
Primary completion
Dec 6, 2013
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; Canadian Cancer Trials Group
- First posted
- Jun 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.
Conditions
- Neoplasms, Breast
Interventions
LapatinibDrug
Small molecule inhibitor
TrastuzumabBiological
Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) at the Primary AnalysisTime frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)
Locations
924 sites in 44 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Anchorage, Alaska
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
Fairfield, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Martinez, California
Novartis Investigative Site
Marysville, California
Novartis Investigative Site
Mountain View, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Pleasanton, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Thornton, Colorado
Novartis Investigative Site
Wheat Ridge, Colorado
Novartis Investigative Site
Hartford, Connecticut
Novartis Investigative Site
New Haven, Connecticut
Novartis Investigative Site
Dover, Delaware
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Lakeland, Florida
Novartis Investigative Site
Ocala, Florida
Novartis Investigative Site
Orlando, Florida
Showing 40 of 924 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.